CoChat

Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency

Open access

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Abstract

The accumulation of undegraded molecular material leads to progressive neurodegeneration in a number of lysosomal storage disorders (LSDs) that are caused by functional deficiencies of lysosomal hydrolases. To determine whether inducing macroautophagy/autophagy via small-molecule therapy would be effective for neuropathic LSDs due to enzyme deficiency, we treated a mouse model of mucopolysaccharidosis IIIB (MPS IIIB), a storage disorder caused by deficiency of the enzyme NAGLU (alpha-N-acetylglucosaminidase [Sanfilippo disease IIIB]), with the autophagy-inducing compound trehalose. Treated naglu–/ – mice lived longer, displayed less hyperactivity and anxiety, retained their vision (and retinal photoreceptors), and showed reduced inflammation in the brain and retina. Treated mice also showed improved clearance of autophagic vacuoles in neuronal and glial cells, accompanied by activation of the TFEB transcriptional network that controls lysosomal biogenesis and autophagic flux. Therefore, small-molecule-induced autophagy enhancement can improve the neurological symptoms associated with a lysosomal enzyme deficiency and could provide a viable therapeutic approach to neuropathic LSDs.Abbreviations: ANOVA: analysis of variance; Atg7: autophagy related 7; AV: autophagic vacuoles; CD68: cd68 antigen; ERG: electroretinogram; ERT: enzyme replacement therapy; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFAP: glial fibrillary acidic protein; GNAT2: guanine nucleotide binding protein, alpha transducing 2; HSCT: hematopoietic stem cell transplantation; INL: inner nuclear layer; LC3: microtubule-associated protein 1 light chain 3 alpha; MPS: mucopolysaccharidoses; NAGLU: alpha-N-acetylglucosaminidase (Sanfilippo disease IIIB); ONL: outer nuclear layer; PBS: phosphate-buffered saline; PRKCA/PKCα: protein kinase C, alpha; S1BF: somatosensory cortex; SQSTM1: sequestosome 1; TEM: transmission electron microscopy; TFEB: transcription factor EB; VMP/VPL: ventral posterior nuclei of the thalamus

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/15548627.2018.1474313

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Trehalose treatment increases the life span and reduces hyperactivity and anxiety-related behavior in naglu−/- mice. Mice were weaned 21 days after birth and immediately treated with 2% trehalose in drinking water. (a) Trehalose increased median and maximum life span (> 6 weeks) of naglu−/- mice (N = 16). (b) Trehalose did not affect mouse body weight (36 weeks of age). (c–f) Open-field analysis of trehalose-treated and untreated naglu−/- mice compared with WT mice at 20 weeks of age (c–d) and 36 weeks of age (e–f). Data are means ± SE. *p ≤ 0.05. ns, not significant.
Figure 1. Trehalose treatment increases the life span and reduces hyperactivity and anxiety-related behavior in naglu−/- mice. Mice were weaned 21 days after birth and immediately treated with 2% trehalose in drinking water. (a) Trehalose increased median and maximum life span (> 6 weeks) of naglu−/- mice (N = 16). (b) Trehalose did not affect mouse body weight (36 weeks of age). (c–f) Open-field analysis of trehalose-treated and untreated naglu−/- mice compared with WT mice at 20 weeks of age (c–d) and 36 weeks of age (e–f). Data are means ± SE. *p ≤ 0.05. ns, not significant.CC BY-NC-ND · PubMed Central
Figure 2. Trehalose treatment improves visual function in naglu−/- mice. (a and b) Representative raw electroretinogram (ERG) traces recorded from untreated (green) and trehalose-treated (purple) naglu−/- mice at 28 and 46 weeks of age. Trehalose-treated mice had slightly higher amplitude of the rod a-wave at 28 weeks, and higher amplitudes of the rod b- and a-waves at 46 weeks. (c and d) Stimulus-response plots showing amplitudes of the dark-adapted ERG b-wave. Data points within the rod operative range were fitted with sigmoidal curves using the Naka-Ruston equation. At 28 weeks of age, the treated naglu−/- mice had a similar maximum response (Bmax) compared to WT mice, which was significantly higher than that of the untreated naglu−/- mice (ANOVA, SNK p < 0.05). At 46 weeks of age, the maximum response of the treated naglu−/- mice was lower than that of the WT mice, but was higher than that of the untreated naglu−/- mice. (e and f) Stimulus-response plots showing amplitudes of the dark-adapted ERG a-wave. At 28 weeks of age, amplitudes of the a-wave recorded from the treated naglu−/- mice were significantly lower than those of the WT mice, but were higher than those of the untreated naglu−/- mice. The intergroup differences progressed further at 46 weeks. Trehalose treatment had no significant effect on cone a-wave. (g and h) There was no significant difference in the amplitude of the cone a-wave between the 3 groups at week 28. Both treated and untreated naglu−/- mice had lower amplitudes of the cone a-wave compared to the WT mice at week 46. (c–h) Data are means (n = 8) ± SE. *p ≤ 0.05, **p ≤ 0.01. ns, not significant.
Figure 2. Trehalose treatment improves visual function in naglu−/- mice. (a and b) Representative raw electroretinogram (ERG) traces recorded from untreated (green) and trehalose-treated (purple) naglu−/- mice at 28 and 46 weeks of age. Trehalose-treated mice had slightly higher amplitude of the rod a-wave at 28 weeks, and higher amplitudes of the rod b- and a-waves at 46 weeks. (c and d) Stimulus-response plots showing amplitudes of the dark-adapted ERG b-wave. Data points within the rod operative range were fitted with sigmoidal curves using the Naka-Ruston equation. At 28 weeks of age, the treated naglu−/- mice had a similar maximum response (Bmax) compared to WT mice, which was significantly higher than that of the untreated naglu−/- mice (ANOVA, SNK p < 0.05). At 46 weeks of age, the maximum response of the treated naglu−/- mice was lower than that of the WT mice, but was higher than that of the untreated naglu−/- mice. (e and f) Stimulus-response plots showing amplitudes of the dark-adapted ERG a-wave. At 28 weeks of age, amplitudes of the a-wave recorded from the treated naglu−/- mice were significantly lower than those of the WT mice, but were higher than those of the untreated naglu−/- mice. The intergroup differences progressed further at 46 weeks. Trehalose treatment had no significant effect on cone a-wave. (g and h) There was no significant difference in the amplitude of the cone a-wave between the 3 groups at week 28. Both treated and untreated naglu−/- mice had lower amplitudes of the cone a-wave compared to the WT mice at week 46. (c–h) Data are means (n = 8) ± SE. *p ≤ 0.05, **p ≤ 0.01. ns, not significant.CC BY-NC-ND · PubMed Central
Figure 3. Trehalose treatment rescues retinal degeneration of naglu−/- mice. Immunofluorescence analyses of retinal neurons were performed using specific markers for cones (GNAT2, panel A, green) and for rod bipolar cell (PRKCA/PKCα, panel B, red) (b) in central and peripheral sections of the retina, together with the TO-PRO3 dye (blue) that stained both rod and cone nuclei. The animals were sacrificed at 46 weeks of age, after the second time point of the electroretinography measurement. Whole retinae of test mice (n = 4 per group) were collected and then hemisected. Using a vibrating microtome, the temporal half of the retina was vertically sectioned and stained. Sections containing the optic nerve head were analyzed. Quantification and statistical analysis of the images show a rescue in the number of both photoreceptors (c) and rod bipolar cells (d) in naglu−/- mice treated with trehalose compared to untreated mice. (e) The thickness of the photoreceptor layer was reduced in untreated naglu−/- mice, but was preserved in trehalose-treated naglu−/- mice. Staining for the inflammatory marker, IBA1, in flat retina sections (f) revealed fewer macrophages/microglia in treated naglu−/- mice compared to untreated mutant mice. The number of IBA1-positive cells/μm2 was significantly reduced in treated naglu−/- mice compared to untreated groups as shown in the graphs (g). Data are means ± SE. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. ns, not significant. Scale bars: (a) and (b) 100 μm, (f) 200 μm.
Figure 3. Trehalose treatment rescues retinal degeneration of naglu−/- mice. Immunofluorescence analyses of retinal neurons were performed using specific markers for cones (GNAT2, panel A, green) and for rod bipolar cell (PRKCA/PKCα, panel B, red) (b) in central and peripheral sections of the retina, together with the TO-PRO3 dye (blue) that stained both rod and cone nuclei. The animals were sacrificed at 46 weeks of age, after the second time point of the electroretinography measurement. Whole retinae of test mice (n = 4 per group) were collected and then hemisected. Using a vibrating microtome, the temporal half of the retina was vertically sectioned and stained. Sections containing the optic nerve head were analyzed. Quantification and statistical analysis of the images show a rescue in the number of both photoreceptors (c) and rod bipolar cells (d) in naglu−/- mice treated with trehalose compared to untreated mice. (e) The thickness of the photoreceptor layer was reduced in untreated naglu−/- mice, but was preserved in trehalose-treated naglu−/- mice. Staining for the inflammatory marker, IBA1, in flat retina sections (f) revealed fewer macrophages/microglia in treated naglu−/- mice compared to untreated mutant mice. The number of IBA1-positive cells/μm2 was significantly reduced in treated naglu−/- mice compared to untreated groups as shown in the graphs (g). Data are means ± SE. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. ns, not significant. Scale bars: (a) and (b) 100 μm, (f) 200 μm.CC BY-NC-ND · PubMed Central
Figure 4. Immunohistochemistry analysis of neuroinflammatory markers in the cortex and thalamus. Immunostaining for astrocytes (GFAP) (a) and microglial cells (CD68) (C) in the somatosensory cortex (S1BF) and the ventral posterior nuclei of the thalamus (VPM/VPL) in trehalose-treated and untreated naglu−/- mice and their respective WT controls. Quantification of GFAP immunoreactivity revealed a significant reduction in astrocytosis in both the cortical and thalamic regions of naglu−/- mice that were treated with trehalose compared to non-treated mutant mice (a). Immunoblot of the whole brain lysate confirmed the significant reduction of astrocytosis at 20 weeks (b). (c) Quantifying CD68 immunoreactivity revealed a small trend in reduction in microglial activation upon trehalose treatment in the cortical region of 40-weeks-old naglu−/- mice. Data are means ± SE. *p ≤ 0.05, **p ≤ 0.01. ns, not significant. Scale bar: 50 μm. A.U, arbitrary units.
Figure 4. Immunohistochemistry analysis of neuroinflammatory markers in the cortex and thalamus. Immunostaining for astrocytes (GFAP) (a) and microglial cells (CD68) (C) in the somatosensory cortex (S1BF) and the ventral posterior nuclei of the thalamus (VPM/VPL) in trehalose-treated and untreated naglu−/- mice and their respective WT controls. Quantification of GFAP immunoreactivity revealed a significant reduction in astrocytosis in both the cortical and thalamic regions of naglu−/- mice that were treated with trehalose compared to non-treated mutant mice (a). Immunoblot of the whole brain lysate confirmed the significant reduction of astrocytosis at 20 weeks (b). (c) Quantifying CD68 immunoreactivity revealed a small trend in reduction in microglial activation upon trehalose treatment in the cortical region of 40-weeks-old naglu−/- mice. Data are means ± SE. *p ≤ 0.05, **p ≤ 0.01. ns, not significant. Scale bar: 50 μm. A.U, arbitrary units.CC BY-NC-ND · PubMed Central
Figure 5. Rescue of vacuolization in brain tissue of naglu−/- mice upon trehalose treatment. TEM images of the cortex (a) and cerebellum (b) from 40-weeks-old naglu−/- mice showed an increased presence of autophagic vacuoles, the site of storage of undigested material, compared to WT controls. Trehalose administration significantly reduced the abundance of autophagic vacuoles in samples from naglu−/- mice, thereby normalizing cellular vacuolization. N = 20 cells per group in cortex and 10 cells per group in cerebellum. The autophagic vacuoles in microglia of the naglu−/- mice were cleared upon trehalose treatment (c). (d) The LC3-II:LC3-I ratio was increased significantly upon trehalose administration. (e) SQSTM1/p62 levels were not changed upon trehalose administration. Data are means ± SE. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. ns, not significant. Scale bar: 2 μm.
Figure 5. Rescue of vacuolization in brain tissue of naglu−/- mice upon trehalose treatment. TEM images of the cortex (a) and cerebellum (b) from 40-weeks-old naglu−/- mice showed an increased presence of autophagic vacuoles, the site of storage of undigested material, compared to WT controls. Trehalose administration significantly reduced the abundance of autophagic vacuoles in samples from naglu−/- mice, thereby normalizing cellular vacuolization. N = 20 cells per group in cortex and 10 cells per group in cerebellum. The autophagic vacuoles in microglia of the naglu−/- mice were cleared upon trehalose treatment (c). (d) The LC3-II:LC3-I ratio was increased significantly upon trehalose administration. (e) SQSTM1/p62 levels were not changed upon trehalose administration. Data are means ± SE. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. ns, not significant. Scale bar: 2 μm.CC BY-NC-ND · PubMed Central
Figure 6. Induction of autophagic flux in photoreceptor cells upon trehalose treatment. (a–c) 661W cells transiently transfected with a plasmid encoding GFP-RFP-LC3 (a) or GFP-RFP-SQSTM1 (c) and treated with trehalose for 72 h showed a decrease in GFP:RFP ratio, indicating increased autophagic flux (b). Arrowheads indicate puncta that are RFP-positive and GFP-negative. (d–f) Knockdown of Atg7 in MEF cells and photoreceptors treated with trehalose decreased LC3-II:LC3-I and LC3-II:GAPDH ratios and did not change SQSTM1/p62 levels. Additional treatment with bafilomycin A1 increased the LC3-II:LC3-I ratio, indicating that treatment with trehalose induces autophagic flux (d–f and h–j). Data are means ± SE. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. ns, not significant. Scale bar: 20 μm.
Figure 6. Induction of autophagic flux in photoreceptor cells upon trehalose treatment. (a–c) 661W cells transiently transfected with a plasmid encoding GFP-RFP-LC3 (a) or GFP-RFP-SQSTM1 (c) and treated with trehalose for 72 h showed a decrease in GFP:RFP ratio, indicating increased autophagic flux (b). Arrowheads indicate puncta that are RFP-positive and GFP-negative. (d–f) Knockdown of Atg7 in MEF cells and photoreceptors treated with trehalose decreased LC3-II:LC3-I and LC3-II:GAPDH ratios and did not change SQSTM1/p62 levels. Additional treatment with bafilomycin A1 increased the LC3-II:LC3-I ratio, indicating that treatment with trehalose induces autophagic flux (d–f and h–j). Data are means ± SE. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. ns, not significant. Scale bar: 20 μm.CC BY-NC-ND · PubMed Central
Figure 7. Trehalose promotes TFEB nuclear translocation and activation of the TFEB transcriptional network in vivo. (a) Immunofluorescence of Purkinje cells showing that TFEB was translocated to the nucleus upon trehalose treatment in both WT and naglu−/- mice. (b) Quantification of the number of cells with TFEB in the nucleus in the indicated genotypes and conditions. (c–d) RT-qPCR analysis of mRNAs extracted from WT (c) or KO (d) brain homogenates showing increased transcriptional levels of TFEB target genes of the autophagy-lysosomal system upon trehalose treatment (n = 3 per group). Data are means ± SE. **p ≤ 0.01. ns, not significant. Scale bar: 30 μm.
Figure 7. Trehalose promotes TFEB nuclear translocation and activation of the TFEB transcriptional network in vivo. (a) Immunofluorescence of Purkinje cells showing that TFEB was translocated to the nucleus upon trehalose treatment in both WT and naglu−/- mice. (b) Quantification of the number of cells with TFEB in the nucleus in the indicated genotypes and conditions. (c–d) RT-qPCR analysis of mRNAs extracted from WT (c) or KO (d) brain homogenates showing increased transcriptional levels of TFEB target genes of the autophagy-lysosomal system upon trehalose treatment (n = 3 per group). Data are means ± SE. **p ≤ 0.01. ns, not significant. Scale bar: 30 μm.CC BY-NC-ND · PubMed Central
Figure 8. Trehalose promotes transcriptional activation of autophagy and lysosomal genes via TFEB. (a–b) MEF cells (a) and photoreceptor cells (b) were transiently transfected with a plasmid encoding TFEB-GFP and treated with trehalose, which resulted in nuclear translocation of TFEB (n = 40–45 cells/condition). (c-d) RT-qPCR analysis showing increased transcriptional levels of TFEB genes of the autophagy-lysosomal system upon trehalose treatment in MEF cells (c) and in photoreceptor cells (d) (n = 3 per group). Knockdown of Tfeb counteracted trehalose-induced transcriptional activation of autophagy-lysosomal genes, demonstrating that trehalose enhances lysosomal function via TFEB. Data are means ± SE. **p ≤ 0.01, ***p ≤ 0.001. Scale bars: 20 μm.
Figure 8. Trehalose promotes transcriptional activation of autophagy and lysosomal genes via TFEB. (a–b) MEF cells (a) and photoreceptor cells (b) were transiently transfected with a plasmid encoding TFEB-GFP and treated with trehalose, which resulted in nuclear translocation of TFEB (n = 40–45 cells/condition). (c-d) RT-qPCR analysis showing increased transcriptional levels of TFEB genes of the autophagy-lysosomal system upon trehalose treatment in MEF cells (c) and in photoreceptor cells (d) (n = 3 per group). Knockdown of Tfeb counteracted trehalose-induced transcriptional activation of autophagy-lysosomal genes, demonstrating that trehalose enhances lysosomal function via TFEB. Data are means ± SE. **p ≤ 0.01, ***p ≤ 0.001. Scale bars: 20 μm.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 78 references

Research works printed but not linked: 2

  1. Gilkes JA, 2014, Pediatr Endocrinol Rev, 12, 133
  2. Hemsley KM, 2009, Int J Clin Pharmacol Ther, 47, S118

Cited by

See all 111

Metadata

Authors
Lotfi, P., Tse, D. Y., Di Ronza, A., Seymour, M. L., Martano, G., Cooper, J. D., Pereira, F. A., Passafaro, M., Wu, S. M., & Sardiello, M.
Affiliations
  • Baylor College of Medicine (US)
  • Hong Kong Polytechnic University (HK)
  • Department of Molecular and Human Genetics, Baylor College of Medicine, Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, TX, USA
  • CNR Institute of Neuroscience, Milan, Italy
  • University of California, Los Angeles (US)
Corresponding author
Sardiello, Marco
Venue
Autophagy
Published
2018-07-23
Volume
14
Issue
8
Pages
1419-1434
ISSN
  • 1554-8627 (ISSN-L)
  • 1554-8635
OpenAlex
W2808836146
Cited by
106
References
78
Citations by year
2026: 8 · 2025: 13 · 2024: 1 · 2023: 11 · 2022: 13 · 2021: 21 · 2020: 22 · 2019: 12 · 2018: 5
FWCI
10.28
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Autophagy (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PolyU Institutional Research Archive (Hong Kong Polytechnic University) (submittedVersion, cc-by-nc-nd)
Funders
  • NIH (NS079618)
  • Brain Disorders and Development Training (T32NS043124-13)
  • IDDRC (1U54 HD083092)
  • Eunice Kennedy Shriver National Institute of Child Health & Human Development (1S10 OD016167)
  • Hong Kong Polytechnic University (G-YBQT)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
Keywords
trehalose, lysosomal storage disease, NAGLU, macroautophagy, neuroinflammation, retinal degeneration, photoreceptors, TFEB, lysosomal biogenesis, autophagic flux, small molecule therapy
MeSH terms
Acetylglucosaminidase, Animals, Astrocytes, Autophagy, Brain, Cell Nucleus, Inflammation, Lysosomes, Mice, Inbred C57BL, Mucopolysaccharidosis III, Retinal Degeneration, Trehalose, Vacuoles, Transcriptional Activation, Survival Analysis, Retinal Rod Photoreceptor Cells, Mice, Knockout, Disease Progression, Retinal Bipolar Cells, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Gene Regulatory Networks

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency. https://app.cochat.ai/papers/10.1080/15548627.2018.1474313
The paper
Lotfi, P., Tse, D. Y., Di Ronza, A., Seymour, M. L., Martano, G., Cooper, J. D., Pereira, F. A., Passafaro, M., Wu, S. M., & Sardiello, M. (2018). Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency. Autophagy. https://doi.org/10.1080/15548627.2018.1474313

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.